scholarly journals Detection of Anti-Human T-Lymphotropic Virus Type I Antibody in Whole Blood by a Novel Counting Immunoassay

2003 ◽  
Vol 49 (2) ◽  
pp. 275-280 ◽  
Author(s):  
Kazunari Yamaguchi ◽  
Yuji Yonemura ◽  
Hiroaki Okabe ◽  
Yoichi Takahama ◽  
Shinya Nagai ◽  
...  
Keyword(s):  
Virus Type ◽  
Whole Blood ◽  
Blood Cells ◽  
Measuring Method ◽  
Sample Volume ◽  
Latex Agglutination ◽  
Blood Collection ◽  
Type I ◽  
Latex Particles ◽  
T Lymphotropic Virus

Abstract Background: Assays to screen for and confirm the presence of the antibody for human T-lymphotropic virus type I (HTLV-I) are currently performed with serum or plasma. We developed and evaluated a new counting immunoassay (CIA) for the detection of HTLV-I antibody in whole blood, using recombinant and synthetic peptide antigens. Methods: We assessed the CIA for detection of HTLV-I antibody in whole blood and plasma. The CIA is an immunity-measuring method that combines latex agglutination with particle-counting technology. The numbers of agglutinated latex particles, single latex particles, and blood cells in a sample are measured based on differences in particle size between latex particles and blood cells. Results: The CIA and ELISA methods were in agreement for all 24 plasma samples tested, including those from 6 patients with HTLV-I-associated diseases, 6 HTLV-I carriers, and 12 HTLV-I antibody-negative individuals. The concordance between the ELISA (plasma) and the CIA (whole blood) for samples from 24 patients was 100%. The concordance between a particle agglutination method (plasma) and the CIA (plasma or whole blood) for 1065 patients was 99.5%. The concordance between results obtained for 1065 pairs of plasma and whole blood samples with the CIA method was 100%. HTLV-I antibody in whole blood was stable for 3 days after blood collection. With this CIA method, results were available within 15 min. Conclusions: The CIA method can be used in screening for HTLV-I. The use of whole blood rather than serum or plasma reduces the sample volume and number of blood collections required, as well as assay time.

scholarly journals Autoantibodies and Immunoglobulins in Atomic Bomb Survivors with Human T-Lymphotropic Virus Type I.

1996 ◽  
Vol 35 (8) ◽  
pp. 624-628 ◽  
Author(s):  
Kiyosumi OHISHI ◽  
Yoshisada SHIBATA ◽  
Tatsufumi NAKAMURA ◽  
Mitsuhiro TSUJIHATA ◽  
Masazumi AKAHOSHI ◽  
...  
Keyword(s):  
Virus Type ◽  
Atomic Bomb ◽  
Type I ◽  
T Lymphotropic Virus ◽  
Atomic Bomb Survivors

scholarly journals Natural History of Viral Markers in Children Infected with Human T Lymphotropic Virus Type I in Jamaica

2006 ◽  
Vol 194 (5) ◽  
pp. 552-560 ◽  
Author(s):  
Elizabeth Margaret Maloney ◽  
Yoshihisa Yamano ◽  
Paul C. VanVeldhuisen ◽  
Takashi Sawada ◽  
Norma Kim ◽  
...  
Keyword(s):  
Natural History ◽  
Virus Type ◽  
Type I ◽  
T Lymphotropic Virus ◽  
History Of

scholarly journals 1707. Clinical Profile of Human T-Lymphotropic Virus Type I Infection in Pediatric Population in a Referral Hospital in Colombia

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S836-S837
Author(s):  
Juliana Mejia- Mertel ◽  
Juan P Rojas -Hernandez
Keyword(s):  
Virus Type ◽  
Low Income ◽  
Pacific Coast ◽  
Vision Loss ◽  
Pediatric Population ◽  
Clinical Manifestations ◽  
Low Income Countries ◽  
Nutritional Deficiencies ◽  
Type I ◽  
T Lymphotropic Virus

Abstract Background The Human T-lymphotropic virus type 1 (HTLV-1), affects around ten to twenty million people worldwide, predominantly in intertropical regions (Africa, Japan, Melanesia, Australia, and South America Pacific Coast). The most common disorders associated are T-cell leukemia/lymphoma (ALT) and HTLV-1-associated myelopathy (HAM). Studies have reported other clinical manifestations in HTLV-1, still studies are needed in pediatric population to improve diagnosis and treatment of infected patients. Methods Descriptive, retrospective cohort study, conducted in our referral pediatric hospital in Cali, Colombia. Included pediatric patients (1 to 18 years of age) diagnosed with HTLV-1 infection, between January 2017 to March 2020. Results Twelve patients were included, seven males and five females. Eleven patients were from and resided in the Colombian Pacific coast. Ten patients showed nutritional deficiencies. None showed clinical or laboratory signs of ALT, neither neurological symptoms or physical exam suggesting HAM. In terms of associated diseases and opportunistic infections, none had a positive HIV ELISA test, and stool tests were all negative for Strongiloydes. Four presented infective dermatitis, and two showed lesions suggesting scabies. Eight patients presented respiratory symptoms with chest CT scans showing signs of chronic inflammation, bronchiectasis, and subpleural bullae as the major findings. Additional tests were carried out in bronchoalveolar fluid, four had positive galactomannan test,suggesting pulmonary aspergillosis, two exhibited positive gene PCR testing for Mycobacterium tuberculosis. Regarding inflammatory diseases, one patient presented with symptoms of Inflammatory Bowl Disease, with biopsy confirming Crohn’s disease. Another patient presente abrupt vision loss, diagnosed with Vogt Koyanagi Hadara Syndrome after ophthalmological evaluation. Summary features HTLV-1 patients Ground-glass opacity diffusely distributed in both lungs with multiple bronchiectasis involving predominantly lung bases. Cystic images diffusely distributed in both lungs, some subpleural and other centrilobular. Conclusion It is important to consider alternative manifestations of HTLV-1 infection in the pediatric population, including pulmonary disease, opportunistic co-infections, and inflammatory disorders. It is crucial to diagnose this disease in childhood to reach a better control of this neglected infection that affects predominantly vulnerable population in low-income countries. Disclosures All Authors: No reported disclosures

scholarly journals Activation of a novel KpnI transcript by downstream integration of a human T-lymphotropic virus type I provirus.

1986 ◽  
Vol 261 (10) ◽  
pp. 4615-4619
Author(s):  
T Okamoto ◽  
M S Reitz ◽  
M F Clarke ◽  
L L Jagodzinski ◽  
F Wong-Staal
Keyword(s):  
Virus Type ◽  
Type I ◽  
T Lymphotropic Virus
Sign in / Sign up

Export Citation Format

Share Document